Tags: Partnership

announcements

ADDF and Harrington Discovery Institute Invite Applications for 2018 ADDF-Harrington Scholar Award

Harrington Discovery Institute and the Alzheimer’s Drug Discovery Foundation (ADDF) announce a request for proposals for the 2018 ADDF-Harrington Scholar Award.

announcements

Funding Supports New Approaches to Treat Multiple Types of Dementia

The ADDF announces two investments in programs targeting mitochondria and the progranulin gene.

blog

Top Five Alzheimer’s Advances in 2017

Our top five advances in 2017 spotlight the substantial progress we have made toward conquering Alzheimer’s and other neurodegenerative diseases.

announcements

New Project Co-Funded with Pfizer’s Centers for Therapeutic Innovation

The Alzheimer's Drug Discovery Foundation (ADDF) and Pfizer's Centers for Therapeutic Innovation (CTI) announced joint support for a project that could result in a therapeutic for neurodegenerative diseases.

announcements

ADDF and Science Exchange Launch ADDF ACCESS to Advance Research

New “CRO Finder” Connects Scientists with Specialized Resources

announcements

Expanded Partnership Increases Support for Drug Discovery

ADDF and Harrington Institute increase funding and resources for promising Alzheimer’s drug discovery programs.

announcements

Lauder and Newhouse Families Announce New Initiative to Find Treatments for Frontotemporal Dementia

The Lauder Foundation, Leonard A. Lauder, President, and Ronald S. Lauder have committed $5 million, which will be combined with $5 million from the Samuel I. Newhouse Foundation to create The Treat FTD Fund. The fund, a joint program of AFTD and the ADDF, will accelerate clinical trials for FTD over the next decade.

announcements

ADDF Joins BIRAX Regenerative Medicine Initiative

The Alzheimer's Drug Discovery Foundation (ADDF) has joined the BIRAX Initiative, which recently issues its third call for proposals. BIRAX brings together British and Israeli scientists to tackle some of the world’s most challenging diseases including cardiovascular and liver disease, diabetes and Parkinson’s. 

announcements

PsychoGenics and the ADDF Announce a Risk-Sharing Partnership for Preclinical Studies

We are partnering with PsychoGenics Inc. to bring its services to our grantees working on preclinical Alzheimer’s drug discovery programs. 

announcements

ADDF and Harrington Discovery Institute Announce 2015 Award Recipients

Collaboration advances development of therapeutics for the treatment of Alzheimer’s Disease.